Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

12 September 2024

Pharmaceutical industry faces pressure to improve patient reach in developing countries

Citizen Digital covers the Access to Medicine Foundation’s latest report, which takes a first-ever look at how some of the largest pharma companies are reaching patients worldwide in pursuit of health equity, especially in low- and middle-income countries (LMICs).

Direct links

Read the full article

The article outlines the progress and notable shortcomings in the pharmaceutical industry's efforts to deliver essential medicines to patients, as detailed in the Foundation's recent report. It then covers a few findings from the report: 

  • 42 different approaches employed by pharma companies were identified, with AstraZeneca, Novartis, and Roche among those working on a more nuanced measurement framework. 

  • 19 of the 20 largest pharmaceutical companies have developed patient outreach methods, however, a unified measurement approach is still lacking. 

  • Many companies are making ambitious commitments to expand their reach in LMICs, yet there is still potential for them to better their efforts to reach those in need. 

  • There are both product and geographic gaps in measuring patient reach, leaving the number of patients reached in some areas and for some diseases unknown. 

“Companies must prioritise patient reach or risk falling short in addressing health inequality,” the article quotes Claudia Martínez, Head of Research at the Foundation. “Our findings lay out a clear path for pharma companies to do this, emphasising how they can embed equitable access within their business operations.” 

Download the full report

Foundation's new report reveals what pharma companies can do to ensure their products reach underserved populations

Download

Media

Read more about our coverage in global media
Featured Media

Drug firms ‘must prioritise underserved patients’

11 September 2024
Featured Media

Pharma’s Patient Reach Problem: Billions Still Left Behind

10 September 2024

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved